<div id="readability-page-1"><div><ul> <li>In March 2026, Daiichi Sankyo and AstraZeneca announced that the U.S. FDA accepted and granted Priority Review to their supplemental Biologics License Application for ENHERTU, targeting adults with HER2 positive breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment.</li> <li>The application rests on DESTINY-Breast05 phase 3 data showing ENHERTU cut the risk of invasive disease recurrence or death versus T-DM1, with three-year invasive disease-free survival of 92.4% compared with 83.7%.</li> <li>We’ll now examine how ENHERTU’s Priority Review and DESTINY-Breast05 outcomes may reshape Daiichi Sankyo’s oncology-focused investment narrative.</li> </ul><p>AI is about to change healthcare. These 6 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</p><h2>Daiichi Sankyo Company Investment Narrative Recap</h2><p>To own Daiichi Sankyo today, you need to believe its antibody drug conjugate platform, especially ENHERTU, can justify concentrated oncology risk and rising R&amp;D spend. The new Priority Review for ENHERTU in residual HER2 positive early breast cancer is a key near term regulatory catalyst, while safety, pricing and competitive pressures around a few blockbuster drugs remain the most important risk. If this filing disappoints or safety scrutiny intensifies, the impact on sentiment could be material.</p> <p>The most relevant recent announcement alongside this news is the EMA’s Type II variation review for ENHERTU in a similar HER2 positive early breast cancer setting in Europe. Taken together with the U.S. Priority Review, these parallel filings highlight how much Daiichi Sankyo’s near term outlook is tied to ENHERTU’s regulatory progress across major markets, reinforcing both the upside potential and the concentration risk around this single drug family.</p> <p>Yet even as ENHERTU’s opportunity expands, investors should be aware of the concentration risk if...</p> <p>Read the full narrative on Daiichi Sankyo Company (it's free!)</p><p>Daiichi Sankyo Company's narrative projects ¥2659.1 billion revenue and ¥447.9 billion earnings by 2028.</p><p>Uncover how Daiichi Sankyo Company's forecasts yield a ¥4949 fair value, a 71% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3da34022-ad84-492d-b476-e9d83a1ae4e6/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3da34022-ad84-492d-b476-e9d83a1ae4e6/chart/quote-price"/><figcaption>TSE:4568 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts already expected revenue to reach about ¥3,508.7 billion and earnings ¥701.9 billion by 2028, so ENHERTU’s latest Priority Review could either reinforce that bullish “faster oncology leadership” view or expose how heavily those forecasts lean on one drug’s success and regulatory timing.</p><p>Explore 2 other fair value estimates on Daiichi Sankyo Company - why the stock might be worth just ¥4023!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Daiichi Sankyo Company research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.</li><li>Our free Daiichi Sankyo Company research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Daiichi Sankyo Company's overall financial health at a glance.</li></ul><h2>Ready To Venture Into Other Investment Styles?</h2><p>The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:</p><ul><li>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.</li><li>We've uncovered the 21 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

DSNKY

<p>Daiichi Sankyo and AstraZeneca's ENHERTU received U.S. FDA Priority Review for treating HER2 positive breast cancer, based on promising phase 3 data. This regulatory milestone could significantly impact Daiichi Sankyo's investment narrative, highlighting both potential upside and concentration risk tied to ENHERTU. Analysts project substantial revenue and earnings growth by 2028, but the success of ENHERTU remains critical. The company's future outlook is closely linked to regulatory progress in major markets, with potential risks if safety concerns arise or if the drug's performance disappoints.</p>

The Bull Case For Daiichi Sankyo Company (TSE:4568) Could Change Following ENHERTU’s Priority Review Success